These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 34767321)

  • 1. Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease.
    Beaton A; Okello E; Rwebembera J; Grobler A; Engelman D; Alepere J; Canales L; Carapetis J; DeWyer A; Lwabi P; Mirabel M; Mocumbi AO; Murali M; Nakitto M; Ndagire E; Nunes MCP; Omara IO; Sarnacki R; Scheel A; Wilson N; Zimmerman M; Zühlke L; Karthikeyan G; Sable CA; Steer AC
    N Engl J Med; 2022 Jan; 386(3):230-240. PubMed ID: 34767321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determining the impact of Benzathine penicillin G prophylaxis in children with latent rheumatic heart disease (GOAL trial): Study protocol for a randomized controlled trial.
    Beaton A; Okello E; Engelman D; Grobler A; Scheel A; DeWyer A; Sarnacki R; Omara IO; Rwebembera J; Sable C; Steer A
    Am Heart J; 2019 Sep; 215():95-105. PubMed ID: 31301533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intramuscular versus enteral penicillin prophylaxis to prevent progression of rheumatic heart disease: Study protocol for a noninferiority randomized trial (the GOALIE trial).
    Rwebembera J; Ndagire E; Carvalho N; Webel AR; Sable C; Okello E; Sarnacki R; Spaziani AM; Mucunguzi A; Engelman D; Grobler A; Steer A; Beaton A
    Am Heart J; 2024 Sep; 275():74-85. PubMed ID: 38797460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Latent Rheumatic Heart Disease: Identifying the Children at Highest Risk of Unfavorable Outcome.
    Beaton A; Aliku T; Dewyer A; Jacobs M; Jiang J; Longenecker CT; Lubega S; McCarter R; Mirabel M; Mirembe G; Namuyonga J; Okello E; Scheel A; Tenywa E; Sable C; Lwabi P
    Circulation; 2017 Dec; 136(23):2233-2244. PubMed ID: 28972003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to secondary antibiotic prophylaxis for patients with rheumatic heart disease diagnosed through screening in Fiji.
    Engelman D; Mataika RL; Kado JH; Ah Kee M; Donath S; Parks T; Steer AC
    Trop Med Int Health; 2016 Dec; 21(12):1583-1591. PubMed ID: 27730711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benzathine penicillin adherence for secondary prophylaxis among patients affected with rheumatic heart disease attending Mulago Hospital.
    Musoke C; Mondo CK; Okello E; Zhang W; Kakande B; Nyakoojo W; Freers J
    Cardiovasc J Afr; 2013 May; 24(4):124-9. PubMed ID: 24217043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Systematic Echocardiographic Screening for Rheumatic Heart Disease in Nepalese Schoolchildren: A Cluster Randomized Clinical Trial.
    Karki P; Uranw S; Bastola S; Mahato R; Shrestha NR; Sherpa K; Dhungana S; Odutayo A; Gurung K; Pandey N; Agrawal K; Shah P; Rothenbühler M; Jüni P; Pilgrim T
    JAMA Cardiol; 2021 Apr; 6(4):420-426. PubMed ID: 33471029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adequate adherence to benzathine penicillin secondary prophylaxis following the diagnosis of rheumatic heart disease by echocardiographic screening.
    Culliford-Semmens N; Tilton E; Webb R; Lennon D; Paku B; Malcolm J; French S; Blair N; Wilson N
    N Z Med J; 2017 Jun; 130(1457):50-57. PubMed ID: 28617789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement in rheumatic fever and rheumatic heart disease management and prevention using a health centre-based continuous quality improvement approach.
    Ralph AP; Fittock M; Schultz R; Thompson D; Dowden M; Clemens T; Parnaby MG; Clark M; McDonald MI; Edwards KN; Carapetis JR; Bailie RS
    BMC Health Serv Res; 2013 Dec; 13():525. PubMed ID: 24350582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The personal and clinical impact of screen-detected maternal rheumatic heart disease in Uganda: a prospective follow up study.
    Voleti S; Okello E; Murali M; Sarnacki R; Majwala A; Ssembatya R; Bakka O; Namisanvu H; Njeri A; Matovu A; DeStigter K; Sable C; Beaton A
    BMC Pregnancy Childbirth; 2020 Oct; 20(1):611. PubMed ID: 33036571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of secondary penicillin prophylaxis on valvular changes in patients with rheumatic heart disease in Far North Queensland.
    Haran S; Crane N; Kazi S; Axford-Haines L; White A
    Aust J Rural Health; 2018 Apr; 26(2):119-125. PubMed ID: 29168587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A population pharmacokinetic study of benzathine benzylpenicillin G administration in children and adolescents with rheumatic heart disease: new insights for improved secondary prophylaxis strategies.
    Hand RM; Salman S; Newall N; Vine J; Page-Sharp M; Bowen AC; Gray K; Baker A; Kado J; Joseph J; Marsh J; Ramsay J; Sika-Paotonu D; Batty KT; Manning L; Carapetis J
    J Antimicrob Chemother; 2019 Jul; 74(7):1984-1991. PubMed ID: 30989171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving Delivery of Secondary Prophylaxis for Rheumatic Heart Disease in a High-Burden Setting: Outcome of a Stepped-Wedge, Community, Randomized Trial.
    Ralph AP; de Dassel JL; Kirby A; Read C; Mitchell AG; Maguire GP; Currie BJ; Bailie RS; Johnston V; Carapetis JR
    J Am Heart Assoc; 2018 Jul; 7(14):. PubMed ID: 30018165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of latent rheumatic heart disease: External validation of a simplified score in patients with and without secondary prophylaxis.
    Nascimento BR; Nunes MCP; da Silva JLP; Steer A; Engelman D; Okello E; Rwebembera J; Zuhlke L; Mirabel M; Nakitto M; Sarnacki R; Ribeiro ALP; Sable CA; Beaton AZ;
    Int J Cardiol; 2024 Mar; 399():131662. PubMed ID: 38141728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever.
    Wyber R; Boyd BJ; Colquhoun S; Currie BJ; Engel M; Kado J; Karthikeyan G; Sullivan M; Saxena A; Sheel M; Steer A; Mucumbitsi J; Zühlke L; Carapetis J
    Drug Deliv Transl Res; 2016 Oct; 6(5):572-8. PubMed ID: 27465618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinic factors associated with better delivery of secondary prophylaxis in acute rheumatic fever management.
    Quinn E; Girgis S; Van Buskirk J; Matthews V; Ward JE
    Aust J Gen Pract; 2019 Dec; 48(12):859-865. PubMed ID: 31774991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with loss of penicillin G concentrations in serum after intramuscular benzathine penicillin G injection: a meta-analysis.
    Broderick MP; Hansen CJ; Faix DJ
    Pediatr Infect Dis J; 2012 Jul; 31(7):722-5. PubMed ID: 22481428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rheumatic heart disease in Uganda: predictors of morbidity and mortality one year after presentation.
    Okello E; Longenecker CT; Beaton A; Kamya MR; Lwabi P
    BMC Cardiovasc Disord; 2017 Jan; 17(1):20. PubMed ID: 28061759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to secondary prevention of rheumatic fever and rheumatic heart disease in young people: an 11-year retrospective study.
    Liaw J; Gorton S; Heal C; White A
    Aust N Z J Public Health; 2022 Dec; 46(6):758-763. PubMed ID: 35616403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.